Doxofylline

Catalog No.S4164 Batch:S416401

Print

Technical Data

Formula

C11H14N4O4

Molecular Weight 266.25 CAS No. 69975-86-6
Solubility (25°C)* In vitro DMSO 53 mg/mL (199.06 mM)
Water 24 mg/mL (90.14 mM)
Ethanol 2 mg/mL (7.51 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Doxofylline (Doxophylline) is a phosphodiesterase inhibitor and a xanthine derivative drug for asthma.
Targets
PDE [1]
In vitro Doxofylline has PDE inhibitor activity and can increase the level of cAMP, which could, therefore, be used for the treatment of asthma and COPD. EC50 value of Doxofylline is 15 times higher than that of aminophylline in inhibiting the adenosine-induced relaxation of tracheal smooth muscle and 10 times higher in reducing the negative inotropic effect induced by adenosine on isolated guinea-pig atria. Doxofylline could effectively decrease the open probability of the calcium-activated potassium channels as a result of both the shortening of open period and the prolongation of close time. Doxofylline has greatly decreased affinity towards adenosine A1 and A2 receptors when compared with theophylline, which may contribute to the better safety profile. Moreover, unlike theophylline, Doxofylline does not interfere with calcium influx into cells nor antagonizes the action of calcium-channel blockers. [1]
In vivo Doxofylline has been shown to have better efficacy with fewer side effects than theophylline. 30 mg/kg Doxofylline increases heart rate of anaesthetized cat by 13 beats/min. The effective therapeutic dose of Doxofylline has less cardio-stimulant effects than Theophylline, such that Doxofylline does not out significantly increase the cardiac frequency nor does it have arrhythmogenic effects. [2]

Protocol (from reference)

Selleck's Doxofylline has been cited by 1 publication

Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins [ J Immunother Cancer, 2022, 10(7)e004159] PubMed: 35820727

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.